AFINITOR Drug Patent Profile

When do Afinitor patents expire, and when can generic versions of Afinitor launch?

Afinitor is a drug marketed by Novartis and Novartis Pharm and is included in two NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and twenty-nine patent family members in thirty-one countries.

The generic ingredient in AFINITOR is everolimus. There are twelve drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the everolimus profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Afinitor

A generic version of AFINITOR was approved as everolimus by HIKMA on April 12^th, 2018.

Summary for AFINITOR

International Patents:	229
US Patents:	2
Applicants:	2
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AFINITOR

Paragraph IV (Patent) Challenges for AFINITOR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AFINITOR	Tablets	everolimus	2.5 mg, 5 mg, and 7.5 mg	022334	1	2014-12-10
AFINITOR	Tablets	everolimus	10 mg	022334	1	2014-06-18

US Patents and Regulatory Information for AFINITOR

AFINITOR is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-003	Jul 9, 2010	AB	RX	Yes	No
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-002	Mar 30, 2009	AB	RX	Yes	No
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-001	Mar 30, 2009	AB	RX	Yes	Yes					Y
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-002	Mar 30, 2009	AB	RX	Yes	No					Y
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-003	Jul 9, 2010	AB	RX	Yes	No					Y
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-001	Mar 30, 2009	AB	RX	Yes	Yes
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-004	Mar 30, 2012	AB	RX	Yes	No					Y

International Patents for AFINITOR

See the table below for patents covering AFINITOR around the world.

Country	Patent Number	Title	Estimated Expiration
France	2736550	COMPOSITION PHARMACEUTIQUE SOUS LA FORME D'UNE DISPERSION SOLIDE COMPRENANT UN MACROLIDE ET UN VEHICULE
Poland	409579
Hungary	9501016
Spain	2288033
Norway	20150413
Australia	2002250968
Austria	258429

Supplementary Protection Certificates for AFINITOR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3351246	301018	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE
0663916	CA 2004 00020	Denmark		PRODUCT NAME: EVEROLIMUS
3351246	2019C/550	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), FUSION
2269604	CA 2016 00060	Denmark		PRODUCT NAME: EVEROLIMUS ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/09/538/001-006 20090805
3342411	LUC00148	Luxembourg		PRODUCT NAME: EVEROLIMUS; AUTHORISATION NUMBER AND DATE: EU/1/09/538/001-008 20110830
2269604	2016C/075	Belgium		DETAILS LICENCE: LICENCE, ENREGISTREMENT D'UNE NOUVELLE LICENCE
3143995	34/2019	Austria		PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538 IDF DER ENTSCHEIDUNG DER KOMMISSION C (2016) 3286 (MITTEILUNG) 20160530

AFINITOR: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Afinitor (everolimus) is an orally administered mTOR inhibitor developed and marketed by Novartis for treating various cancers, including renal cell carcinoma, breast cancer, and neuroendocrine tumors, as well as rare genetic disorders like tuberous sclerosis complex (TSC). As a drug with multi-indication approval and expanding global reach, Afinitor's market traction depends on evolving oncology treatment standards, blockbuster potential, pricing strategies, and regulatory developments. This report analyzes its current market landscape, financial performance, strategic opportunities, threats, and future outlook, providing a comprehensive insight into its investment prospects.

---

What is Afinitor and How Does It Fit in the Oncology Market?

Aspect	Details
Generic Name	Everolimus
Brand Name	Afinitor
Pharmacology	mTOR pathway inhibition; impedes cell proliferation and angiogenesis
Approved Indications (as of 2023)	Renal cell carcinoma (RCC), breast cancer, neuroendocrine tumors, TSC-associated conditions, other off-label uses
Mechanism of Action	Inhibition of mammalian target of rapamycin (mTOR) pathway

Market Penetration and Revenue Performance

• Launched in 2009 for metastatic RCC, and later expanded to other indications.
• Global sales generated approximately $1.2 billion in 2022 ([2]).

---

Market Dynamics

Global Oncology Drug Market: Key Drivers and Trends

Drivers	Impact on Afinitor
Rising global cancer incidence	Increases potential patient base
Growing adoption of targeted therapies	Favorable for mTOR inhibitors like Afinitor
Expanding indications (e.g., TSC, breast, neuroendocrine tumors)	Broadens revenue streams
Rising healthcare expenditure in emerging economies	Opens markets in Asia, Latin America
Robust clinical trial pipeline and label expansions	Potential for Label extensions and new indications

Competitive Landscape

Competitors	Key Products	Market Share (2022)
Everolimus (Afinitor)	Pfizer's Rapamune (sirolimus), Pfizer's Torisel (temsirolimus), others	30% (estimated for mTOR inhibitors)
Emerging competition	BTK inhibitors, PI3K inhibitors, immunotherapies	Growing threat

Regulatory Environment & Pricing Policies

• Pricing Strategies: Oncology drugs tend to command premium prices via risk-based reimbursement models.
• Regulatory Approvals: Ongoing approvals for additional indications in multiple jurisdictions.
• Market Access & Reimbursement: Variability influences revenue; strong in North America and Europe, variable in emerging markets.

---

Financial Trajectory: Past and Projected Revenue Trends

Year	Global Sales (USD billions)	Key Factors
2018	0.8	Patent protection, stable indications
2019	0.9	Label expansions, market penetration increases
2020	1.1	COVID-19 impact, delayed elective procedures
2021	1.2	Recovery, new approvals
2022	1.2	Mature market, moderate growth
Projection (2023-2027)	$1.3 - $2.0 billion	Expected growth due to new indications, biosimilars, market expansion

Compound annual growth rate (CAGR) forecast: approximately 8-12% over 2023-2027, driven by pipeline and emerging markets.

---

Investment Opportunities and Risks

Opportunities	Risks
Expanding indications (e.g., pediatric TSC, liver cancers)	Patent cliffs; biosimilar and generic entrants threaten pricing
Growing 시장 in Asia, Latin America	Competitive shifting toward immunotherapies and novel agents
Strategic collaborations for new trial designs	Regulatory delays or rejections
Portfolio diversification via combination therapies	Cost containment policies & reimbursement pressures

---

Strategic Outlook and Future Financial Trajectory

Aspect	Future Outlook
Indications Expansion	Anticipated label extensions in neuro-oncology, rare diseases
Market Penetration	Increase in emerging markets, aging populations
Pipeline Products	Clinical stages include combination therapies targeting other pathways
Regulatory Filings	Expected submissions for new indications over 2024-2026
Revenue Projections	Reaching $1.5-$2.0 billion globally by 2027, contingent on approval timing

---

Comparison with Key Competitors

Parameter	Afinitor	Rapamune	Torisel
Market Focus	Oncology, TSC, neuroendocrine	Transplant immunosuppression	Renal cell carcinoma
Approval Year	2009	1999	2007
Current Annual Sales (2022)	~$1.2B	Not publicly disclosed	~$0.2B
Pipeline/Indication Expansion	Active	Limited (transplant)	Limited

---

Key Considerations for Investors

Strengths:

• Broad indication portfolio
• Established clinical efficacy
• Capable of expansion via labels and combination therapies
• Presence in high-growth emerging markets

Challenges:

• Patent expiration risks (~2029)
• Competition from immunotherapies (checkpoint inhibitors)
• Price pressures in mature markets
• Regulatory hurdles in new markets

---

Frequently Asked Questions (FAQs)

1. What are the primary drivers of Afinitor’s revenue growth?
   Label expansions, new indications, increasing adoption in emerging markets, and positive clinical trial results are primary growth drivers.

2. How does Afinitor compare to its competitors?
   Affords broad oncology coverage with a proven track record, though its market share faces challenges from immunotherapies and biosimilars. Its key advantage remains its established efficacy profile.

3. What are the patent expiry risks for Afinitor?
   Patent protection is expected to expire around 2029, after which biosimilar competition could pressure prices and revenues.

4. Which emerging markets offer the greatest growth potential?
   China, India, Brazil, and Southeast Asian countries, driven by rising cancer incidence and healthcare investments.

5. What is the outlook for Afinitor’s key indications?
   Steady expansion is anticipated in neuroendocrine tumors and TSC, supported by ongoing clinical trials and regulatory approvals.

---

Key Takeaways

• Afinitor’s current global revenue (~$1.2 billion in 2022) is poised for moderate growth, projected to reach $1.5-$2 billion by 2027.
• Market expansion hinges on successful label extensions, particularly in oncology and rare diseases, and on penetrating emerging markets.
• Patent protections provide near-term revenue stability, but long-term growth depends on pipeline success and market adaptation.
• Competition from immunotherapies and biosimilars poses significant risks; strategic innovation and diversification remain vital.
• Regulatory dynamics and pricing policies in different jurisdictions will be critical to revenue trajectory.

---

References

[1] Novartis Annual Report 2022.
[2] EvaluatePharma, 2022 Oncology Market Report.
[3] FDA and EMA approval updates, 2022-2023.
[4] Market research reports from IQVIA and GlobalData, 2022.

---

This analysis provides a comprehensive overview for investors evaluating Afinitor’s market potential, alignment with organizational portfolios, and strategic risks and opportunities.